WCLC 2025 - Posters & ePosters-P1.17.80 Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC) in Spain

P1.17.80 Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK+ Non-Small Cell Lung Cancer (NSCLC) in Spain

Back to course

Pdf Summary

This study evaluates the economic burden of disease management and recurrences following complete surgical resection and adjuvant platinum-based chemotherapy (PbCH) in patients with early-stage anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (eNSCLC) in Spain. Using a 3-state Markov model over a 5-year horizon from the payer perspective, the analysis estimated direct healthcare costs associated with recurrent disease, which remains a major challenge despite current standard treatment.<br /><br />A hypothetical cohort of 98 eNSCLC ALK patients was modeled, with clinical inputs sourced from the ALINA study and expert consensus involving oncologists and hospital pharmacists. Results showed that 62 (63%) of these patients would experience recurrence within five years post-adjuvant PbCH. The total 5-year cost for managing all patients was €9,226,675, with recurrence-related costs accounting for €8,519,175 of this amount. The average cost per recurrence was €137,026, varying by treatment modality: approximately €9,576 for local treatments (e.g., surgery or stereotactic body radiation therapy) and €172,973 for systemic therapies (such as TKIs like lorlatinib, alectinib, or chemotherapy agents).<br /><br />Treatment patterns for recurrence comprised predominantly systemic therapies (78%), with local treatments used in 22% of cases. The model’s sensitivity analysis confirmed the robustness of findings and highlighted key cost drivers. The study underscores that although early-stage ALK NSCLC patient numbers are relatively low, recurrence management imposes a substantial financial burden on Spain’s health system.<br /><br />The authors conclude that earlier and more effective adjuvant treatments beyond current PbCH are urgently needed to reduce recurrence rates and optimize cost-effective disease management. The analysis was funded by Roche Farma and incorporated insights from both clinical experts and health economic data sources.

Asset Subtitle

Rocío Gordo

Meta Tag

Speaker Rocío Gordo

Topic Global Health, Health Services, and Health Economics

Keywords

economic burden

early-stage ALK positive NSCLC

platinum-based chemotherapy

disease recurrence

Markov model

healthcare costs

systemic therapies

local treatments

Spain health system

cost-effectiveness